142 related articles for article (PubMed ID: 37839709)
1. Risk of cytomegalovirus infection and subsequent allograft failure after pancreas transplantation.
Yetmar ZA; Kudva YC; Seville MT; Bosch W; Huskey JL; Jarmi T; Kukla A; Dean PG; Razonable RR; Beam E
Am J Transplant; 2024 Feb; 24(2):271-279. PubMed ID: 37839709
[TBL] [Abstract][Full Text] [Related]
2. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of cytomegalovirus infection after pancreas transplantation.
Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC
Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269
[TBL] [Abstract][Full Text] [Related]
4. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
5. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant.
Lin A; Brown S; Chinapen S; Lee YJ; Seo SK; Ponce DM; Shahid Z; Giralt S; Papanicolaou GA; Perales MA; Shaffer BC
Blood Adv; 2023 Dec; 7(23):7153-7160. PubMed ID: 37906513
[TBL] [Abstract][Full Text] [Related]
6. High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Lam S; Boan P; Polistena P; Cannell P; Cooney J; Wright M; Purtill D
Transpl Infect Dis; 2021 Aug; 23(4):e13633. PubMed ID: 33978289
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
[TBL] [Abstract][Full Text] [Related]
8. Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a "Safe Corridor" after kidney transplantation?
El Helou G; Lahr B; Razonable R
Transpl Infect Dis; 2021 Apr; 23(2):e13489. PubMed ID: 33037728
[TBL] [Abstract][Full Text] [Related]
9. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus transmission in mismatched solid organ transplant recipients: Are factors other than anti-viral prophylaxis at play?
Hernandez C; Mabilangan C; Burton C; Doucette K; Preiksaitis J
Am J Transplant; 2021 Dec; 21(12):3958-3970. PubMed ID: 34174153
[TBL] [Abstract][Full Text] [Related]
11. Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation.
Belga S; MacDonald C; Chiang D; Kabbani D; Shojai S; Abraldes JG; Cervera C
Clin Infect Dis; 2021 Mar; 72(5):845-852. PubMed ID: 32025704
[TBL] [Abstract][Full Text] [Related]
12. Late-onset allograft rejection, cytomegalovirus infection, and renal allograft loss: Is anti-CMV prophylaxis required following late-onset allograft rejection?
Rahimishahmirzadi M; Jevnikar AM; House AA; Luke PP; Humar A; Silverman MS; Shalhoub SM; Hosseini-Moghaddam SM
Clin Transplant; 2021 Jun; 35(6):e14285. PubMed ID: 33713374
[TBL] [Abstract][Full Text] [Related]
13. CMV allograft pancreatitis: diagnosis, treatment, and histological features.
Klassen DK; Drachenberg CB; Papadimitriou JC; Cangro CB; Fink JC; Bartlett ST; Weir MR
Transplantation; 2000 May; 69(9):1968-71. PubMed ID: 10830244
[TBL] [Abstract][Full Text] [Related]
14. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
Gardiner BJ; Nierenberg NE; Chow JK; Ruthazer R; Kent DM; Snydman DR
Clin Infect Dis; 2018 Oct; 67(9):1395-1402. PubMed ID: 29635432
[TBL] [Abstract][Full Text] [Related]
15. Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant.
Aziz F; Jorgenson MR; Parajuli S; Zhong W; Hidalgo LG; Djamali A; Mandelbrot D; Odorico J; Sollinger H; Astor BC; Mohamed MA
Transpl Infect Dis; 2020 Jun; 22(3):e13272. PubMed ID: 32112710
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.
Saullo JL; Li Y; Messina JA; Thompson J; Dalton T; Giri VK; Reed SD; Miller R; Horwitz ME; Alexander BD; Sung AD
Biol Blood Marrow Transplant; 2020 Mar; 26(3):568-580. PubMed ID: 31712193
[TBL] [Abstract][Full Text] [Related]
17. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
19. Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults.
Politikos I; Lau C; Devlin SM; Quach S; Lin A; Perales MA; Shah GL; Seo SK; Papanicolaou GA; Barker JN
Blood Adv; 2022 Dec; 6(24):6291-6300. PubMed ID: 35802462
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review.
Sepassi A; Saunders IM; Bounthavong M; Taplitz RA; Logan C; Watanabe JH
J Am Pharm Assoc (2003); 2023; 63(4):1138-1149. PubMed ID: 37207713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
